Portola/Novartis Plan Phase III Trial For Elinogrel, With Eyes For Plavix Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Portola's anti-thrombotic vision: Execs discuss possibilities for two partnered, Phase III ready drugs - elinogrel and betrixaban.
You may also be interested in...
Portola's Heart Bypass Drug Gets Closed Advisory Committee Session
FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.
Portola's Heart Bypass Drug Gets Closed Advisory Committee Session
FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.
Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin
The attributes of Merck/Portola's Factor Xa inhibitor betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting